The fresh funds will be used to expand clinics, invest in AI-driven healthcare, and enhance patient engagement, strengthening ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) yesterday. The company’s shares ...

Allogene Therapeutics Inc. (ALLO) on Thursday reported a loss of $59.9 million in its fourth quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 28 ...

Momentum Builds Across Programs with Key Data Milestones Expected in 2025Cemacabtagene Ansegedleucel (Cema-Cel): First-Line ...

Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support ...

Based on its cash, cash equivalents and investments as of December 31, the company continues to expect its cash runway to fund operations into ...

Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream inf ...

In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI ...

Shanghai has emerged as a major hub for CAR-T cell therapy, drawing international patients to the city for the high-end ...

Kingsway Drive East 957: Belinda M. Weston to Jasmine M. Ezeb, $265,000. Lafayette St. 632: W. Harvey III to Thomas L. Claverie, $125,000. Wall Blvd. 525: Ronald A. Gasser to Ronald A. Gasser, ...

S&P 500 E-Mini futures (ESH25) are down -0.21%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.36% this morning as ...